[Ip-health] India - Patent Barriers for Covid-19 Medicines

Paul Fehlner pfehlner at revisiontx.com
Thu Apr 2 19:04:30 PDT 2020


It seems worthwhile to wait to see (1) if remdesivir is actually safe and effective so as to justify approval to treat COVID-19; and (2) allow Gilead the first opportunity to provide the drug before proposing a compulsory license. There is no doubt that governments — including IP friendly America — have the power to issue compulsory licenses when an essential therapeutic is not available to the citizens of the country. Let’s not douse a building with water before a fire has started. 

Paul Fehlner
President & CEO
reVision Therapeutics, Inc.
+1.201.966.7474
pfehlner at revisiontx.com
www.revisiontx.com



> On Apr 2, 2020, at 12:51 PM, K.M. Gopakumar <kumargopakm at gmail.com> wrote:
> 
> Drugs That Could Be Used to Beat COVID-19 Have Another Barrier – Patents
> https://thewire.in/law/remdesivir-favipravir-covid-19-patents-indian-patents-act-ustr
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org



More information about the Ip-health mailing list